Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes

Thrombosis and Haemostasis - Tập 114 Số 09 - Trang 478-789 - 2015
Waltraud C. Schrottmaier, Julia B. Kral‐Pointner, Sigrun Badrnya, Alice Assinger1
1Dr. Alice Assinger, Centre for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, A-1090 Vienna, Austria, Tel.: +43 1 40160 31405, E-mail: [email protected].

Tóm tắt

SummaryPlatelets are key players in haemostasis and represent a pivotal link between inflammation, immunity and atherogenesis. Depending on the (patho)physiological environment platelets modulate various leukocyte functions via release of inflammatory mediators and direct cell-cell interactions. Elevated levels of circulating platelet-leukocyte aggregates are found in patients suffering from several thrombotic or inflammatory conditions. Platelet-monocyte and platelet-neutrophil interaction can trigger pro- and anti-inflammatory responses and modulate effector functions of all leukocyte subpopulations. These platelet-mediated immune responses have implications for the progression of cardiovascular diseases and also play a crucial role during infections, cancer, transplantations and other inflammatory diseases of several organs. Antiplatelet therapy including the COX inhibitor aspirin and/or ADP receptor P2Y12 inhibitors such as clopidogrel, prasugrel and ticagrelor are the therapy of choice for various cardiovascular complications. Both aspirin and P2Y12 inhibitors attenuate platelet-leukocyte interactions, thereby also modulating immune responses. This may have beneficial effects in some pathological conditions, while it might be detrimental in others. This review aims to summarise the current knowledge on platelet-leukocyte interactions and the impact of aspirin and P2Y12 inhibition on platelet-mediated immune responses and to give an overview on the effects of antiplatelet therapy on platelet-leukocyte interplay in various diseases.

Từ khóa


Tài liệu tham khảo

10.1161/01.RES.0000252802.25497.b7

10.1160/TH13-04-0341

10.1161/CIRCRESAHA.113.300512

10.1189/jlb.0209117

Rinder, 1991, Blood, 78, 1730, 10.1182/blood.V78.7.1730.1730

10.1189/jlb.0907615

10.1189/jlb.0708400

10.1111/j.1538-7836.2011.04235.x

10.1182/blood-2007-01-069195

Burnier, 2009, Thromb Haemost, 101, 439, 10.1160/TH08-08-0521

10.1159/000339857

10.1172/JCI118575

Lievens, 2009, Thromb Haemost, 102, 206, 10.1160/TH09-01-0029

10.4049/jimmunol.173.3.2060

Vasina, 2013, Am J Blood Res, 3, 107

10.1161/ATVBAHA.113.302919

10.1002/eji.1830210406

10.1186/2050-7771-2-1

10.1002/jbm.a.10155

Amirkhosravi, 1996, Thromb Haemost, 75, 87, 10.1055/s-0038-1650226

10.1182/blood-2011-06-359430

10.1111/j.1538-7836.2005.01603.x

10.1038/nm810

10.1182/blood-2010-01-261206

Scheuerer, 2000, Blood, 95, 1158, 10.1182/blood.V95.4.1158.004k31_1158_1166

10.4049/jimmunol.0901368

10.1161/CIRCRESAHA.109.199505

Erbel C, et al. CXCL4-induced plaque macrophages can be specifically identified by co-expression of MMP7+S100A8+ in vitro and in vivo. Innate Immun 2014; Epub ahead of print

10.1096/fj.06-6265fje

10.4049/jimmunol.1201103

10.1161/ATVBAHA.113.303113

10.1038/nm1565

10.1016/j.blre.2006.06.001

10.1182/blood-2012-09-459636

10.1182/blood-2006-08-040980

Diacovo, 1996, Blood, 88, 146, 10.1182/blood.V88.1.146.146

10.1006/bcmd.1995.0025

10.1182/blood-2012-06-437392

10.1007/s00011-012-0446-6

10.1097/SLA.0b013e3181bd95b7

10.1089/ars.2013.5298

10.1111/j.1538-7836.2011.04606.x

10.1111/j.1538-7836.2011.04193.x

10.1097/MOH.0b013e3283324f97

10.1038/nri3024

10.1182/blood-2013-04-496661

10.1126/science.273.5272.252

10.1016/S1074-7613(03)00177-8

10.1189/jlb.1104669

10.1172/JCI71858

10.1111/j.1538-7836.2010.03983.x

10.1161/ATVBAHA.107.141515

10.1016/j.clim.2009.05.006

10.4049/jimmunol.172.9.5297

10.1126/scitranslmed.3001001

10.1186/1471-2172-9-54

10.1182/blood.V99.10.3676

10.1056/NEJMoa010746

10.1111/bcpt.12156

10.2741/1939

10.1016/j.jacc.2005.03.079

10.1161/01.CIR.0000053559.46158.AD

Miedzobrodzki, 2010, Acta Pol Pharm, 67, 487

10.1160/TH12-03-0206

10.1016/j.thromres.2003.08.026

10.1074/jbc.M507762200

10.1161/01.CIR.85.3.1077

10.1161/01.ATV.0000225288.74170.dc

10.1016/j.clpt.2005.08.002

Evangelista, 2005, Thromb Haemost, 94, 568, 10.1160/TH05-01-0020

10.1111/j.1538-7836.2007.02838.x

10.1067/mcp.2003.13

Braun, 2008, Thromb Haemost, 100, 626, 10.1160/TH08-05-0313

10.1056/NEJMoa0706482

10.1182/blood-2014-03-562876

10.1007/s11302-012-9303-x

10.1007/s00395-009-0073-8

10.1371/journal.pone.0069093

10.1097/TP.0b013e318221d407

10.1016/j.thromres.2011.06.016

10.2174/138161212803251853

10.1160/TH13-08-0653

10.1160/THS10-11-0720

10.1002/hep.26950

10.1038/sj.bjp.0707578

10.1002/hep.23435

10.1038/nm1780

10.1073/pnas.1209182109

10.1016/j.jhep.2013.05.040

10.1007/s10157-008-0119-5

10.1111/j.1523-1755.2004.00630.x

10.1007/BF00866739

10.3748/wjg.v20.i12.3180

10.1053/j.gastro.2006.12.027

10.1172/JCI35874

10.4103/0253-7613.96357

10.7326/0003-4819-156-5-201203060-00007

10.1111/j.1365-2036.2011.04784.x

10.1080/09537100802082249

10.1016/j.jdermsci.2008.08.019

Tamagawa-Mineoka R, et al. Platelets play important roles in the late phase of the immediate hypersensitivity reaction. J Allergy Cin Immunol 2009; 123: 581-587, e1-9

10.1254/jphs.08R32FM

10.1097/MBC.0b013e328010bd05

10.1111/bjd.12285

10.1111/j.0022-202X.2004.22318.x

Wu S, et al. Use of Aspirin, Nonsteroidal Anti-inflammatory Drugs, and Aceta-minophen (Paracetamol), and Risk of Psoriasis and Psoriatic Arthritis: A Cohort Study. Acta Derm Venereol 2014; Epub ahead of print

10.4103/0253-7613.125194

10.3109/09537100903165174

10.1046/j.1365-2141.2001.03101.x

10.1111/j.1600-6143.2008.02473.x

10.1038/nrmicro3269

10.1073/pnas.1207314109

10.1161/ATVBAHA.114.303287

10.3389/fimmu.2014.00649

10.1097/QAI.0b013e31828a292c

10.1160/TH14-02-0126

10.1073/pnas.1005743107

Xiang, 2013, Nature Commun, 4, 2657, 10.1038/ncomms3657

10.1146/annurev-physiol-030212-183752

10.2174/1381612811209023260

10.1097/SHK.0b013e3182a384f0

10.1182/blood-2011-10-384826

Nieswandt, 1999, Cancer Res, 59, 1295

10.1016/S0140-6736(12)60209-8

10.1371/journal.pone.0080780

10.1002/ijc.28947

10.1016/j.clbc.2013.08.006

Thông tin
Thông tin xuất bản

Thrombosis and Haemostasis

Tập 114 Số 09

478-789

Thông tin tác giả